Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Receivables - Net (2022 - 2024)

Historic Receivables - Net for Avidity Biosciences (RNA) over the last 3 years, with Q1 2024 value amounting to $1.6 million.

  • Avidity Biosciences' Receivables - Net changed N/A to $1.6 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.6 million, marking a year-over-year change of. This contributed to the annual value of $1.1 million for FY2023, which is 5325.72% down from last year.
  • According to the latest figures from Q1 2024, Avidity Biosciences' Receivables - Net is $1.6 million.
  • In the past 5 years, Avidity Biosciences' Receivables - Net registered a high of $2.4 million during Q4 2022, and its lowest value of $1.1 million during Q4 2023.
  • In the last 3 years, Avidity Biosciences' Receivables - Net had a median value of $1.4 million in 2023 and averaged $1.6 million.
  • Within the past 5 years, the most significant YoY rise in Avidity Biosciences' Receivables - Net was 5325.72% (2023), while the steepest drop was 5325.72% (2023).
  • Over the past 3 years, Avidity Biosciences' Receivables - Net (Quarter) stood at $2.4 million in 2022, then tumbled by 53.26% to $1.1 million in 2023, then soared by 42.53% to $1.6 million in 2024.
  • Its Receivables - Net was $1.6 million in Q1 2024, compared to $1.1 million in Q4 2023 and $1.2 million in Q2 2023.